these mice has been demonstrated by the fact that conditionally immortalized mouse myoblasts will act as normal muscle satellite cells when reintroduced into mouse muscle [4] . Somewhat surprisingly, this does not result in tumour formation despite the fact the cells had been transfected and selected, a process requiring over 60 passages in vitro [4] .
Introduction
The Bio-MEMS (biological-micro-electromechanical machines) sector is experiencing an un-paralleled period of growth, using technologies which involve the use of silicon micromachining to produce highly functional miniaturized devices. A major driving force behind this is the rapidly emerging biochip market. Here, techniques originally used in MEMS are integrated with advanced techniques from molecular biology, physics, chemistry and data exploration. These new Bio-MEMS products, including Lab-on-a-chip (LOAC) devices and DNA microarrays, aim to address a wide range of life science applications, including drug discovery, clinical and environmental diagnostics, and drug delivery. Expansion of the biochip sector is predicted to be one of the key drivers in the overall growth of the microsystems technology (MST) market. Currently, this is valued at £400 million and accounts for 5 % of MST activity. Biochips will thus have a profound impact on many aspects of the life science industries in the 21st century.
The marriage of biological techniques and tools with microfabricated silicon, glass or plastic material devices is resulting in a multitude of start-up companies addressing the lucrative pharmaceutical, biotechnology and diagnostics markets. Most companies in these sectors focus on DNA technologies, particularly capillary separations or microarray formats. These techniques recognize short sequences of DNA or RNA, which can be used for gene-expression profiling (demonstrating which genes are switched on) and detection of single-nucleotide polymorphismsbest summarized as DNA diagnostics. However, within the context of the flow of biological information, drug companies are looking downstream of DNA to find out what happens to proteins and cells from a functional perspective. A range of post-genomic methods, such as protein microarrays and cell chips, are now emerging to address this aspect of life sciences research and development.
MST and drug discovery
Biochips promise to be among the most important pharmaceutical research-and-development tools of the post-genomic era. Comprised of microarrays of genetic, protein or cellular materials on flat or three-dimensional microfluidic devices, these miniature platforms can perform the parallel analysis required to exploit the growth in data from sequencing the human genome.
In 2001 protein chips will make up less than 10 % of this market, rising to 40 % by 2005. It is also expected that 20 % of the biochip market will be LOAC products by 2005. These technologies will hold the dominant share of the DNA-, protein-and cell-chip industry output by 2010. LOAC products will aim to integrate sample preparation, detection and analysis on a single chip, and are already finding wide application in the drug-discovery process, including combinatorial chemistry, target identification and validation, predictive toxicology, high-throughput screening and clinical drug safety.
The advantages of LOAC and biochips
Miniaturized LOAC and biochip methods are being pioneered in both academic and industrial research groups. This has resulted in a wide variety of analytical formats with considerable advantages over existing macroscale technologies. In this respect, many biological recognition events, including specific binding reactions such as DNA-DNA, DNA-RNA, protein-protein and protein-small-molecule interactions, are diffu-sion-limited. Under micro-sized conditions, the reduction in the physical length of the assay, and hence the diffusion length of the reactants, increases with the reaction speed. The increased surface-area-to-volume ratio also ensures that immobilized molecules, as might be the case in protein-or DNA-binding arrays, see the assay solution more quickly. The reduced volumes used in microsystems lower the thermal mass, enabling rapid heating and cooling (pertinent in on-chip PCR, for example). Furthermore, reduced assay volumes reduce reagent costs. This is very important when considering that some DNA probes can cost as much as £1 million\g. Miniaturization may lead to assay intensification, with higher titre densities, lower volumes, reduced material costs and increased throughput. This is particularly important in drug discovery, which uses combinatorial libraries where hundreds of thousands of candidates are generated.
The techniques used in LOAC and microarrays are adapted from the MST and semiconductor industry, and therefore provide an established route to packaging and industrialization. New and unique formats, such as highthroughput single-cell, patch-clamp and fluorescence measurements, can also be made and will have significant future impacts.
In summary, biochip use is growing rapidly as the drug-discovery community accepts the benefits. Simultaneously, macroscale drugscreening strategies, such as conventional microplate-based screens, are running into technical, process and logistical problems in identifying and rationalizing new drug compounds.
Commercial exploitation
A strong indicator of the growing interest in biochips is the investment by venture capitalists in LOAC and biochip companies -often referred to as tool companies. Despite the overall slowdown in venture capitalist funding for high-tech companies, approx. US$120 million was invested in biochip companies in the first quarter of 2001. This equals the total amount invested in the whole sector in 2000. The current climate for raising venture capitalist funding for biochip companies therefore remains positive. Indeed, historically, during times of economic fluctuation, companies addressing the pharmaceutical and biotechnology sector become increasingly favoured.
One spin-off company that has benefited from venture capitalist funding is Adaptive Profiling (APL), formed in May 2001 by the author. APL combines intellectual property with expertise in LOACs, cellular assay techniques, protein microarrays and bio-informatics. It is developing three platform technologies : adaptive and cellular arrays, and an integrated scheduling and bio-informatics software package known as the Adaptive Screening Environment (' ASE '). Collectively, these technology platforms provide drug-discovery companies with an alternative approach to lead compound identification, reducing the importance of random screening of compound libraries. The approach should help overcome many limitations of the existing drug-
Figure 1
Functional protein elements Molecular graphic of a binding protein, showing the binding of a small molecule to its binding site, an action that results in modulation in the fluorescence signal.
Figure 2

Field-stimulation technologies
The principle of placing different recombinant protein variants (A-I) on to a microarray. Elements in the array give a differential output for different compounds. discovery paradigm, enabling pharmaceutical companies to develop products more quickly and at a lower research-and-development cost.
APL combines protein and cellular array technology with sophisticated data-mining tools to enable an automated, high-information screening strategy to be implemented. Only compounds that fit closely the desired pharmaceutical and toxicological profile of the disease target under investigation are passed on to a primary cell-based screening regime for testing. This leads to a smaller number of qualified compounds being passed on to lead optimization activities.
Adaptive arrays
This technology exploits a proprietary drugprofiling methodology, which uses non-specific, or promiscuous, protein-sensor arrays. These arrays allow the function of a sample ligand, such as a potential drug compound, to be classified in the context of known and proven medicines, using its interactions with proteins as the primary mechanism. The presence of a particular functionality within the drug candidate is indicated by the overall pattern of responses across the protein array, rather than by the response of a particular protein sensor tuned for the specific feature.
Adaptive arrays use protein arrays to predict the broad pharmacological and toxicological characteristics of small molecules. The various proteins within the arrays are each derived from a common structure and act as a sensor element. They are produced by recombinant DNA technology and contain a fluorophore (as an optical reporter or probe) near the protein's ligand-binding site (see Figure 1 ). Care is taken to start with a stable and robust protein scaffold, which has a proven ability to bind with a wide range of compounds. Compound classification occurs through a process in which an array is trained with compounds of known pharmacological activity, including already successful drugs and related compounds (see Figure 2 ). These training sets provide characteristic and reproducible responses as a consequence of the protein-drug interactions. They are stored and used as reference data from which library compounds, with unknown characteristics, will be later classified. When compounds from a combinatorial library (containing candidates of unknown function) are subsequently
Figure 3
Micrograph of a field-stimulated electrically active cell (myocyte)
Here a microsytems format is implemented, which provides one route towards functional cellbased assays that is currently being explored. The cell is being electrically based at a frequency of $ 1 Hz.
Figure 4
Integrating electrical pacing Sequence of micrographs, showing the distribution of Ca 2 + within the myocyte, during electrophysiological field stimulation using microsystems technology.
exposed to the protein array, there is a differential optical response, which is then analysed using sophisticated neural network and\or Bayesian inference techniques. This informatics package enables a rapid comparison between the training data and large sets of experimental results. Candidates with protein-binding mechanisms that match those of already known substances are highlighted. Adaptive arrays, therefore, provide a means of classifying and stratifying pharmaceutical leads (a concept known as profiling), contained within libraries of compounds, based upon their predicted toxicological and pharmacological properties. Importantly, the most common mode of action of all medicines is with a protein receptor, giving considerable credibility to the overall strategy of library classification and drug discovery by measuring small-moleculeprotein interactions.
Results
The result is a panel of target-dependent proteomic assays, within a microfluidic network, which will be used in a rapid, high-information pre-screening regime. Combining this information with data-mining software enables the targeted selection of compound library subsets to be taken into a primary cell-based screening regime.
In this latter context, the cellular arrays are proprietary high-information, high-density cellular screening platforms that enable multiple physiological processes to be monitored directly in the cellular environment. The platforms allow the low-volume, low-cost screening of fast ionchannel and protein-transporter mechanisms within cell assays previously thought intractable at the high-throughput-screening level (see Figures 3 and 4) . The company is also developing an innovative assay technique within a LOAC format that enables further compound validation, based on intracellular toxicology and pharmacology.
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